• 2: OUR PRODUCTS
  • 2.1: Oralmat Drops
  • 2.2: Oralmat Wound Healing Spray
  • 2.3: Acno Cream
  • 2.4: FAQs
• 3: ORDER
• 5: CASE STUDIES
  • 5.1: Case Study 1: Oralmat and Asthma
  • 5.2: Case Study 2: Oralmat and Cancer
  • 5.3: Case Study 3: Oralmat and CNS
  • 5.4: Case Study 4: Oralmat and HIV

  • Current page is 5.5: Case Study 5: Oralmat and HSV

• 6: BLOG
• 7: ABOUT US
• 8: CONTACT US

• 5.1: Case Study 1: Oralmat and Asthma
• 5.2: Case Study 2: Oralmat and Cancer
• 5.3: Case Study 3: Oralmat and CNS
• 5.4: Case Study 4: Oralmat and HIV

• Current page is 5.5: Case Study 5: Oralmat and HSV

testimonials

I am very happy to have dealt with your site. Its an honor to be a customer of yours.

- Sachin Makhija

read more >>

 

about us

As a good solutions company we offer our clients a staple of products and services. Our core of which is  read more >>

 

back to home page >>

Case Study 5: Oralmat and HSV

Oralmat Study on human simplex virus

Dr. Greg Tannock, a well known Professor of Virology from the Department of Biotechnology and Environmental Biology, RMIT University, Melbourne, Australia conducted experiments with Oralmat on a strain of herpes simplex virus that was obtained from the Victorian Infectious Diseases Reference Laboratory. During the experiment, Oralmat Drops, in vitro, showed an effect on the infectivity of HSV-1.
 

Following is the complete article.

ANTIVIRAL DRUG ASSAY FOR HSV-1 (ORALMAT DROPS)

• Aim
      To investigate whether Oralmat™ Drops can cause inhibition of HSV-1 in vitro
 
• Materials:
- Vero cells
- HSV-1
- MEM + Hepes (2.8% NaHCO3 + 5% New Born Serum)
- DMEM/F12 +1% Carboxyl Methyl Cellulose (2.8% NaHCO¬3 + 2% New Born Serum)
- DMEM/F12 (2.8% NaHCO3 + 2% New Born Serum)
- 24-well plate and 175cm2 tissue culture flask
- Methanol and 1% crystal violet

• Methods
1) Cytotoxicity assay
- The solution was diluted in DMEM/F12 (eg 1:2, 5, 10, 20, 50, 100, 200 and 500) then 1ml of each dilution was added onto confluent Vero cell monolayer on 24-well plate.
- That plate was incubated at 37oC incubator up to 7 days and examined everyday.
2) Antiviral Drug Assay
- Made the treatment in DMEM/F12 (1:50, 100, 200, 500, 1000 and no drug).
- 300ul of each treatment was added on the cell monolayer then incubated 37oC for 1 hour.
- Removed the treatment then infected HSV-1 (neat up to 10-8 including control which is PBS, in duplicate).
- Left to be adsorbed for half an hour.
- Added DMEM/F12 + 1% CMC overlay containing same concentration as the treatment.
- Incubated at 37oC for 4 days.
3) Staining
- On 4th day of incubation, overlay was removed and then fixed with methanol for 10 minutes.
- Stained with 1% crystal violet for 30 seconds then washed with water.
- Counted plaques and examined the plaque size.
 
• Results
1) Neat up to 1:20 of the solution were toxic to Vero. 1:50 was end point.
2) Plaque number and size (refers to the attached photos)

	Control	1:50	1:100	1:200	1:500	1:1000
PFU mL-1 x 107	8.64	2.05	4.77	6.36	4.32	5.68
Plaque size and shape	Mostly 0.1mm	Less than 0.1mm, the smallest				Mostly 0.1mm
Cell structure loss on 10-4 (App.)	90%	60-70%	70-80%	70-80%	70-80%	90%

* Plaque size couldn’t be measured since they are very tiny.

• Discussion

In this assay, Oralmat™ Drops, in vitro, showed an effect on the infectivity of HSV-1. Compared to 1:50 and control, plaque numbers and size were significantly reduced in the 1:50 plate. It showed that the PFU was reduced by a factor of 4 with 1:50. In addition, 1:50 plate showed a significant reduction of plaque production on the 10-4 well when compared to control and higher dilutions. As fas as drug was diluted, plaque size and number were less different to control. In this assay, plaque size was not measured because of tiny shape but was examined roughly.
In conclusion, this result indicates that Oralmat™ Drops can decrease infectivity of HSV-1.